AnaptysBio, Inc. reported $238M of revenue over the trailing twelve months, +93% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $238M (to Q2 2026). Net income: $196M, trailing twelve months to Q2 2026. Free cash flow: $10M, trailing twelve months to Q2 2026. Operating margin: 95%, trailing twelve months to Q2 2026.

ANABAnaptysBio, Inc.

Healthcare

$45.97+231% 1Y

$45.97

$13.9752 weeks$69.82

ANAB as reported

AnaptysBio, Inc. reported $238M of revenue over the trailing twelve months, +93% on the year before. 9 reported series are charted on this page, each one as filed.

$238M

Revenue, trailing twelve months · to Q2 2026 · +93% against the twelve months before

Net income: $196M
Net income · −248% year on year · trailing twelve months to Q2 2026
Free cash flow: $10M
Free cash flow · −108% year on year · trailing twelve months to Q2 2026
Operating margin: 95%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ANAB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$238M	+93%	Q2 2026
Net income	$196M	−248%	Q2 2026
EPS	$5.74	−236%	Q2 2026
Operating margin	95%	n/a	Q2 2026
Net margin	132%	n/a	Q2 2026
ROE	473%	n/a	Q2 2026
ROA	6.5%	n/a	Q2 2026
ROIC	−767%	n/a	Q4 2020 · 22 quarters behind
Free cash flow	$10M	−108%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.